Understanding alternative splicing of Cav 1.2 calcium channels for a new approach towards individualized medicine

Journal of Biomedical Research

Volumn 24, Issue 3, 2010, Pages 181-186

  Liao, Ping ^a   Soong, Tuck Wah ^a,b  

^a NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIHYDROPYRIDINE DERIVATIVE; BENZOTHIAZEPINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL L TYPE CAV 1,2; DIBENZOTHIAZEPINE DERIVATIVE; ISRADIPINE; PHENYLALKYLAMINE; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; BINDING SITE; CALCIUM TRANSPORT; CARDIOVASCULAR DISEASE; DISEASE SEVERITY; DRUG BINDING; DRUG INHIBITION; DRUG SENSITIVITY; EXON; GENE MUTATION; GENETIC VARIABILITY; HEART ARRHYTHMIA; HEART FAILURE; HEART HYPERTROPHY; HEART INFARCTION; HUMAN; HYPERTENSION; MEDICINE; NONHUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE; TISSUE SPECIFICITY;

EID: 78549291058     PISSN: 16748301     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1674-8301(10)60027-9     Document Type: Review

References (49)

1. Catterall WA Structure and regulation of voltage-gated Ca2+ channels. Annu Rev Cell Dev Biol 2000, 16:521-555.
2. Stieber J, Hofmann F, Ludwig A Pacemaker channels and sinus node arrhythmia. Trends Cardiovasc Med 2004, 14:23-28.
3. Abernethy DR, Schwartz JB Calcium-antagonist drugs. N Engl J Med 1999, 341:1447-1457.
4. Striessnig J, Grabner M, Mitterdorfer J, Hering S, Sinnegger MJ, Glossmann H Structural basis of drug binding to L Ca2+ channels. Trends Pharmacol Sci 1998, 19:108-115.
5. Erne P, Bolli P, Bertel O, Hulthen UL, Kiowski W, Muller FB, et al. Factors influencing the hypotensive effects of calcium antagonists. Hypertension 1983, 5:II97-II102.
6. Wilson TW, Quest DW Comparative pharmacology of calcium antagonists. Can J Cardiol 1995, 11:243-249.
7. Bremer T, Man A, Kask K, Diamond C CACNA1C polymorphisms are associated with the efficacy of calcium channel blockers in the treatment of hypertension. Pharmacogenomics 2006, 7:271-279.
8. Abernethy DR, Soldatov NM Structure-functional diversity of human L-type Ca2+ channel: perspectives for new pharmacological targets. J Pharmacol Exp Ther 2002, 300:724-728.
9. Liao P, Yong TF, Liang MC, Yue DT, Soong TW Splicing for alternative structures of Cav1.2 Ca2+ channels in cardiac and smooth muscles. Cardiovasc Res 2005, 68:197-203.
10. Tang ZZ, Liang MC, Lu S, Yu D, Yu CY, Yue DT, et al. Transcript scanning reveals novel and extensive splice variations in human l-type voltage-gated calcium channel, Cav1.2 alpha1 subunit. J Biol Chem 2004, 279:44335-44343.
11. Tiwari S, Zhang Y, Heller J, Abernethy DR, Soldatov NM Atherosclerosis-related molecular alteration of the human CaV1.2 calcium channel {alpha}1C subunit. Proc Natl Acad Sci U S A 2006, 103:17024-17029.
12. Cheng X, Liu J, Asuncion-Chin M, Blaskova E, Bannister JP, Dopico AM, et al. A novel Ca(V)1.2 N terminus expressed in smooth muscle cells of resistance size arteries modifies channel regulation by auxiliary subunits. J Biol Chem 2007, 282:29211-29221.
13. Liao P, Yu D, Li G, Yong TF, Soon JL, Chua YL, et al. A smooth muscle Cav1.2 calcium channel splice variant underlies hyperpolarized window current and enhanced state-dependent inhibition by nifedipine. J Biol Chem 2007, 282:35133-35142.
14. Liao P, Yu D, Lu S, Tang Z, Liang MC, Zeng S, et al. Smooth muscle-selective alternatively spliced exon generates functional variation in Cav1.2 calcium channels. J Biol Chem 2004, 279:50329-50335.
15. Welling A, Ludwig A, Zimmer S, Klugbauer N, Flockerzi V, Hofmann F Alternatively spliced IS6 segments of the alpha 1C gene determine the tissue-specific dihydropyridine sensitivity of cardiac and vascular smooth muscle L-type Ca2+ channels. Circ Res 1997, 81:526-532.
16. Hockerman GH, Peterson BZ, Johnson BD, Catterall WA Molecular determinants of drug binding and action on L-type calcium channels. Annu Rev Pharmacol Toxicol 1997, 37:361-396.
17. Striessnig J Pharmacology, structure and function of cardiac L-type Ca(2+) channels. Cell Physiol Biochem 1999, 9:242-269.
18. Huber IG, Wappl-Kornherr E, Sinnegger-Brauns MJ, Hoda JC, Walter-Bastl D, Striessnig J Opposite effects of a single IIIS5 mutation on phenylalkylamine and dihydropyridine interaction with L-type Ca2+ channels. J Biol Chem 2004, 279:55211-55217.
19. Lee KS, Tsien RW Mechanism of calcium channel blockade by verapamil, D600, diltiazem and nitrendipine in single dialysed heart cells. Nature 1983, 302:790-794.
20. Triggle DJ Calcium-channel drugs: structure-function relationships and selectivity of action. J Cardiovasc Pharmacol 1991, 18(Suppl 10):S1-S6.
21. Nelson MT, Standen NB, Brayden JE, Worley JF Noradrenaline contracts arteries by activating voltage-dependent calcium channels. Nature 1988, 336:382-385.
22. Hadley RW, Lederer WJ Properties of L-type calcium channel gating current in isolated guinea pig ventricular myocytes. J Gen Physiol 1991, 98:265-285.
23. Mikami A, Imoto K, Tanabe T, Niidome T, Mori Y, Takeshima H, et al. Primary structure and functional expression of the cardiac dihydropyridine-sensitive calcium channel. Nature 1989, 340:230-233.
24. Biel M, Ruth P, Bosse E, Hullin R, Stuhmer W, Flockerzi V, et al. Primary structure and functional expression of a high voltage activated calcium channel from rabbit lung. FEBS Lett 1990, 269:409-412.
25. Hu H, Marban E Isoform-specific inhibition of L-type calcium channels by dihydropyridines is independent of isoform-specific gating properties. Mol Pharmacol 1998, 53:902-907.
26. Morel N, Buryi V, Feron O, Gomez JP, Christen MO, Godfraind T The action of calcium channel blockers on recombinant L-type calcium channel alpha1-subunits. Br J Pharmacol 1998, 125:1005-1012.
27. Zhang JF, Ellinor PT, Aldrich RW, Tsien RW Molecular determinants of voltage-dependent inactivation in calcium channels. Nature 1994, 372:97-100.
28. Kamp TJ, Hell JW Regulation of cardiac L-type calcium channels by protein kinase A and protein kinase C. Circ Res 2000, 87:1095-1102.
29. Keef KD, Hume JR, Zhong J Regulation of cardiac and smooth muscle Ca(2+) channels (Ca(V)1.2a,b) by protein kinases. Am J Physiol Cell Physiol 2001, 281:C1743-C1756.
30. van der Heyden MA, Wijnhoven TJ, Opthof T Molecular aspects of adrenergic modulation of cardiac L-type Ca2+ channels. Cardiovasc Res 2005, 65:28-39.
31. Shistik E, Ivanina T, Blumenstein Y, Dascal N Crucial role of N terminus in function of cardiac L-type Ca2+ channel and its modulation by protein kinase C. J Biol Chem 1998, 273:17901-17909.
32. McHugh D, Beech DJ Protein kinase C requirement of Ca2+ channel stimulation by intracellular ATP in guinea-pig basilar artery smooth muscle cells. J Physiol 1997, 500(Pt 2):311-317.
33. Bielefeldt K Molecular diversity of voltage-sensitive calcium channels in smooth muscle cells. J Lab Clin Med 1999, 133:469-477.
34. Tang ZZ, Hong X, Wang J, Soong TW Signature combinatorial splicing profiles of rat cardiac- and smooth-muscle Ca(v)1.2 channels with distinct biophysical properties. Cell Calcium 2007, 41:417-428.
35. Fleischmann BK, Murray RK, Kotlikoff MI Voltage window for sustained elevation of cytosolic calcium in smooth muscle cells. Proc Natl Acad Sci U S A 1994, 91:11914-11918.
36. Zuhlke RD, Bouron A, Soldatov NM, Reuter H Ca2+ channel sensitivity towards the blocker isradipine is affected by alternative splicing of the human alpha1C subunit gene. FEBS Lett 1998, 427:220-224.
37. Soldatov NM, Bouron A, Reuter H Different voltage-dependent inhibition by dihydropyridines of human Ca2+ channel splice variants. J Biol Chem 1995, 270:10540-10543.
38. Wang D, Papp AC, Binkley PF, Johnson JA, Sadee W Highly variable mRNA expression and splicing of L-type voltage-dependent calcium channel alpha subunit 1C in human heart tissues. Pharmacogenet Genomics 2006, 16:735-745.
39. Seisenberger C, Specht V, Welling A, Platzer J, Pfeifer A, Kuhbandner S, et al. Functional embryonic cardiomyocytes after disruption of the L-type alpha1C (Cav1.2) calcium channel gene in the mouse. J Biol Chem 2000, 275:39193-39199.
40. Liao P, Zhang HY, Soong TW Alternative splicing of voltage-gated calcium channels: from molecular biology to disease. Pflugers Arch 2009, 458:481-487.
41. Splawski I, Timothy KW, Decher N, Kumar P, Sachse FB, Beggs AH, et al. Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc Natl Acad Sci U S A 2005, 102:8089-8096. discussion 8086-8088.
42. Splawski I, Timothy KW, Sharpe LM, Decher N, Kumar P, Bloise R, et al. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 2004, 119:19-31.
43. Diebold RJ, Koch WJ, Ellinor PT, Wang JJ, Muthuchamy M, Wieczorek DF, et al. Mutually exclusive exon splicing of the cardiac calcium channel alpha 1 subunit gene generates developmentally regulated isoforms in the rat heart. Proc Natl Acad Sci U S A 1992, 89:1497-1501.
44. Gidh-Jain M, Huang B, Jain P, Battula V, el-Sherif N Reemergence of the fetal pattern of L-type calcium channel gene expression in non infarcted myocardium during left ventricular remodeling. Biochem Biophys Res Commun 1995, 216:892-897.
45. Yang Y, Chen X, Margulies K, Jeevanandam V, Pollack P, Bailey BA, et al. L-type Ca2+ channel alpha 1c subunit isoform switching in failing human ventricular myocardium. J Mol Cell Cardiol 2000, 32:973-984.
46. Tang ZZ, Liao P, Li G, Jiang FL, Yu D, Hong X, et al. Differential splicing patterns of L-type calcium channel Cav1.2 subunit in hearts of Spontaneously Hypertensive Rats and Wistar Kyoto Rats. Biochim Biophys Acta 2008, 1783:118-130.
47. Liao P, Li G, Yu de J, Yong TF, Wang JJ, Wang J, et al. Molecular alteration of Ca(v)1.2 calcium channel in chronic myocardial infarction. Pflugers Arch 2009, 458:701-711.
48. Wielowieyski PA, Wigle JT, Salih M, Hum P, Tuana BS Alternative splicing in intracellular loop connecting domains II and III of the alpha 1 subunit of Cav1.2 Ca2+ channels predicts two-domain polypeptides with unique C-terminal tails. J Biol Chem 2001, 276:1398-1406.
49. Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, Hoffman SM, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 1996, 87:543-552.